Akoya Biosciences(AKYA) ZACKS·2025-05-05 15:05Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Akoya Biosciences, driven by higher revenues, but actual results compared to estimates will significantly influence stock price movements [1][2]. Financial Expectations - Akoya is expected to report a quarterly loss of 19.88 million, which is an increase of 8.3% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate for Akoya has remained unchanged over the last 30 days, indicating stability in analyst expectations [4]. - The Most Accurate Estimate for Akoya is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +20.69%, suggesting a more optimistic outlook from analysts [10]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a favorable Zacks Rank [8]. - However, Akoya currently holds a Zacks Rank of 4, which complicates the prediction of an earnings beat despite the positive Earnings ESP [11]. Historical Performance - In the last reported quarter, Akoya was expected to post a loss of 0.17, resulting in a surprise of -13.33% [12]. - Over the past four quarters, Akoya has only beaten consensus EPS estimates once [13]. Industry Comparison - Illumina, another player in the biomedical and genetics industry, is expected to report earnings of 1.04 billion, down 3.5% from the previous year [17]. - Illumina's consensus EPS estimate has been revised 0.6% lower in the last 30 days, but a higher Most Accurate Estimate has resulted in an Earnings ESP of 0.18%, indicating a likelihood of beating the consensus EPS estimate [18].